Multiway
Development of a new multiplex technology adapted to Point of Care diagnosis
Lorem Ipsum
Lorem ipsum dolore sit atmet
Study cases
Multiway
Development of a new multiplex technology adapted to Point of Care diagnosis
Key words
Key words
Key words
Key words
Key words
Key words
Background
BIOASTER has received a grant from the Bill & Melinda Gates Foundation to develop high sensitive and multiplex rapid diagnostics with Mologic Ltd and Global Health Labs Inc
Challenges
While Lateral Flow Assays (LFA) are highly valued as inexpensive, quick, and easy to use in the developing countries, the technology has historically lacked the high sensitivity achieved with the laboratory analytical reference methods.
BIOASTER will leverage its breakthrough Col/Im technology to develop, from feasibility to prototype readiness, a unique, low sample-volume, high-sensitive multiplex reagent platform.
Solution
BIOASTER has harnessed the high-affinity interaction of specific bacterial proteins, the Colicin family and its counterpart, the Immunity proteins as a solid-phase immunoassay technology platform in which one binding partner is deployed as a tag and the other as a capture molecule, offering a much-needed alternative (or addition)
to the long-established avidin/biotin tag-capture system perfectly, adapted to point of care diagnosis.
The primary outcome of this project is to demonstrate the potential of the Col/Im technology as a versatile tool for high sensitive, multiplex diagnostics, through the development of multiplex immunoassay and nucleic acid amplification LFA.
Results
The project has started in December 2021
Outlook
With demonstrated success, this technology will be immediately applicable to several diagnostic applications to fulfil unmet needs for high-performance multiplex rapid tests,